Michael A. Den Bakker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael A. Den Bakker has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
Alexander Marx
Institute of Pathology University Medical Centre Mannheim, University of Heidelberg Mannheim Germany
5 shared publications- Anja C. Roden
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
3 shared publications - Carolien H. M. van Deurzen
Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
3 shared publications - Geert J. L. H. van Leenders
Department of Pathology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, The Netherlands
3 shared publications - Margaretha A. van der Slot
Department of Pathology Erasmus MC Cancer Institute, University Medical Center Rotterdam the Netherlands
3 shared publications Melanie Gan
Anser Prostate Operation Clinic Rotterdam the Netherlands
3 shared publications
Latest Publications
- Open Access
- 17 October 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 249
Diagnostic challenges in WHO classification of thymic epithelial tumors: The clinical value of an international expert pathology panel
- 17 October 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 249
Open AccessDiagnostic challenges in WHO classification of thymic epithelial tumors: The clinical value of an international expert pathology panel
- Open Access
- 15 September 2026
- Published by Elsevier in ESMO Rare Cancers
- Vol. 8
Feasibility of active surveillance for atypical lipomatous tumors and impact on quality of life: interim analysis of the MINIMALIST trial
- 15 September 2026
- Published by Elsevier in ESMO Rare Cancers
- Vol. 8
Open AccessFeasibility of active surveillance for atypical lipomatous tumors and impact on quality of life: interim analysis of the MINIMALIST trial
- Open Access
- 1 June 2026
- Published by AME Publishing Company in Mediastinum
- Vol. 10, 32
Thymolipoma and lipofibroadenoma, two sides of the same coin?
- 1 June 2026
- Published by AME Publishing Company in Mediastinum
- Vol. 10, 32
Open AccessThymolipoma and lipofibroadenoma, two sides of the same coin?
- Open Access
- 20 November 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 106 (1) , 104261
Interassay Comparison With Digital Image Analysis of 4 Routine Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry Assays in Primary Breast Cancer and Its Metastasis
- 20 November 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 106 (1) , 104261
Open AccessInterassay Comparison With Digital Image Analysis of 4 Routine Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry Assays in Primary Breast Cancer and Its Metastasis
- Open Access
- 11 June 2024
- Published by Wiley in Histopathology
- Vol. 85 (4) , 639-648
Mismatch repair deficiency: how reliable is the two‐antibody approach? A national real‐life study
Aims: Traditionally, mismatch repair (MMR) status is determined by a panel of four antibodies (MLH1, PMS2, MSH2, MSH6). If all proteins are retained, cases are MMR proficient (pMMR), while loss of one or more proteins is indicative of MMR deficiency (dMMR). This approach has been challenged in favour of a two‐antibody approach, using PMS2 and MSH6 as a first screening. Their retainment is deemed sufficient to declare cases pMMR. In this study we aim to verify the validity of the two‐antibody approach.Methods and Results: We performed a nationwide study in colorectal cancer (CRC) and endometrial cancer (EC) diagnosed between 2016 and 2023, including 47,657 patients to evaluate the two‐antibody approach. In 0.17% and 0.4% of cases of CRC and EC, respectively, dMMR cases would be missed with the two‐antibody approach. Subgroup analyses pointed towards slightly increased miss rates in younger patients (under the age of 50 years) in both groups and identified special subtypes (signet ring cell carcinoma, medullary carcinoma, and mucinous carcinoma in CRC and clear cell carcinoma in EC) with increased miss rates. For these specific subgroups, a low threshold should be used for further testing. In case of ambiguous or heterogeneous staining patterns, four antibodies should be used.Conclusion: In general, the application of a two‐antibody MMR testing strategy does not lead to considerable failure of dMMR identification and saves costs.
- 11 June 2024
- Published by Wiley in Histopathology
- Vol. 85 (4) , 639-648
Open AccessMismatch repair deficiency: how reliable is the two‐antibody approach? A national real‐life study
Aims: Traditionally, mismatch repair (MMR) status is determined by a panel of four antibodies (MLH1, PMS2, MSH2, MSH6). If all proteins are retained, cases are MMR proficient (pMMR), while loss of one or more proteins is indicative of MMR deficiency (dMMR). This approach has been challenged in favour of a two‐antibody approach, using PMS2 and MSH6 as a first screening. Their retainment is deemed sufficient to declare cases pMMR. In this study we aim to verify the validity of the two‐antibody approach.Methods and Results: We performed a nationwide study in colorectal cancer (CRC) and endometrial cancer (EC) diagnosed between 2016 and 2023, including 47,657 patients to evaluate the two‐antibody approach. In 0.17% and 0.4% of cases of CRC and EC, respectively, dMMR cases would be missed with the two‐antibody approach. Subgroup analyses pointed towards slightly increased miss rates in younger patients (under the age of 50 years) in both groups and identified special subtypes (signet ring cell carcinoma, medullary carcinoma, and mucinous carcinoma in CRC and clear cell carcinoma in EC) with increased miss rates. For these specific subgroups, a low threshold should be used for further testing. In case of ambiguous or heterogeneous staining patterns, four antibodies should be used.Conclusion: In general, the application of a two‐antibody MMR testing strategy does not lead to considerable failure of dMMR identification and saves costs.
- Open Access
- 28 September 2023
- Published by Wiley in Histopathology
- Vol. 84 (1) , 238-252
Neurogenic tumours of the posterior mediastinum and differential diagnosis considerations
The mediastinal compartment harbours vital organs and structures, including the heart, great vessels, major airways, and thymus. These structures are embedded in and associated with soft‐tissue elements consisting of adipose and fibro‐collagenous tissue in which soft‐tissue tumours may develop. A detailed inventory of soft‐tissue tumours that may be encountered in the mediastinum based on the WHO 2013 classification was published in 2015. In addition, several comprehensive reviews on mediastinal soft‐tissue pathology are available, including reviews focusing specifically on a single tumour type. This review will focus on primary neurogenic and spindle cell tumours of the somatic soft tissue of the posterior mediastinum and provide a discussion of the pertinent differential diagnoses.
- 28 September 2023
- Published by Wiley in Histopathology
- Vol. 84 (1) , 238-252
Open AccessNeurogenic tumours of the posterior mediastinum and differential diagnosis considerations
The mediastinal compartment harbours vital organs and structures, including the heart, great vessels, major airways, and thymus. These structures are embedded in and associated with soft‐tissue elements consisting of adipose and fibro‐collagenous tissue in which soft‐tissue tumours may develop. A detailed inventory of soft‐tissue tumours that may be encountered in the mediastinum based on the WHO 2013 classification was published in 2015. In addition, several comprehensive reviews on mediastinal soft‐tissue pathology are available, including reviews focusing specifically on a single tumour type. This review will focus on primary neurogenic and spindle cell tumours of the somatic soft tissue of the posterior mediastinum and provide a discussion of the pertinent differential diagnoses.
- 18 September 2023
- Published by Wiley in Histopathology
- Vol. 83 (6) , 967-980
Dataset for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR)
Aims: Thymic epithelial tumours (TET), including thymomas and thymic carcinomas and thymic neuroendocrine neoplasms, are malignant neoplasms that can be associated with morbidity and mortality. Recently, an updated version of the World Health Organization (WHO) Classification of Thoracic Tumours 5th Edition, 2021 has been released, which included various changes to the classification of these neoplasms. In addition, in 2017 the Union for International Cancer Control (UICC) / American Joint Committee on Cancer (AJCC) published the 8th Edition Staging Manual which, for the first time, includes a TNM staging that is applicable to thymomas, thymic carcinomas, and thymic neuroendocrine neoplasms.Methods and Results: To standardize reporting of resected TET and thymic neuroendocrine neoplasms the accrediting bodies updated their reporting protocols. The International Collaboration on Cancer Reporting (ICCR), which represents a collaboration between various National Associations of Pathology, updated its 2017 histopathology reporting guide on TET and thymic neuroendocrine neoplasms accordingly. This report will highlight important changes in the reporting of TET and thymic neuroendocrine neoplasms based on the 2021 WHO, emphasize the 2017 TNM staging, and also comment on the rigour and various uncertainties for the pathologist when trying to follow that staging.Conclusion: The ICCR dataset provides a comprehensive, standardized template for reporting of resected TET and thymic neuroendocrine neoplasms.
- 18 September 2023
- Published by Wiley in Histopathology
- Vol. 83 (6) , 967-980
Dataset for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR)
Aims: Thymic epithelial tumours (TET), including thymomas and thymic carcinomas and thymic neuroendocrine neoplasms, are malignant neoplasms that can be associated with morbidity and mortality. Recently, an updated version of the World Health Organization (WHO) Classification of Thoracic Tumours 5th Edition, 2021 has been released, which included various changes to the classification of these neoplasms. In addition, in 2017 the Union for International Cancer Control (UICC) / American Joint Committee on Cancer (AJCC) published the 8th Edition Staging Manual which, for the first time, includes a TNM staging that is applicable to thymomas, thymic carcinomas, and thymic neuroendocrine neoplasms.Methods and Results: To standardize reporting of resected TET and thymic neuroendocrine neoplasms the accrediting bodies updated their reporting protocols. The International Collaboration on Cancer Reporting (ICCR), which represents a collaboration between various National Associations of Pathology, updated its 2017 histopathology reporting guide on TET and thymic neuroendocrine neoplasms accordingly. This report will highlight important changes in the reporting of TET and thymic neuroendocrine neoplasms based on the 2021 WHO, emphasize the 2017 TNM staging, and also comment on the rigour and various uncertainties for the pathologist when trying to follow that staging.Conclusion: The ICCR dataset provides a comprehensive, standardized template for reporting of resected TET and thymic neuroendocrine neoplasms.
- Open Access
- 1 June 2023
- Published by AME Publishing Company in Mediastinum
- Vol. 7, 19
Asymptomatic lipofibroadenoma in a 17-year-old male: a case report and literature review of a rare entity
Original Article Asymptomatic lipofibroadenoma in a 17-year-old male: a case report and literature review of a rare entity Michael A. den Bakker, Marijn A. Vermeulen, Cornelis P. van de Ven, Simone A. J. ter Horst, Lennart Kester, Ronald R. de Krijger
- 1 June 2023
- Published by AME Publishing Company in Mediastinum
- Vol. 7, 19
Open AccessAsymptomatic lipofibroadenoma in a 17-year-old male: a case report and literature review of a rare entity
Original Article Asymptomatic lipofibroadenoma in a 17-year-old male: a case report and literature review of a rare entity Michael A. den Bakker, Marijn A. Vermeulen, Cornelis P. van de Ven, Simone A. J. ter Horst, Lennart Kester, Ronald R. de Krijger
- Open Access
- 4 May 2023
- Published by Wiley in Histopathology
- Vol. 83 (3) , 348-356
Biopsy prostate cancer perineural invasion and tumour load are associated with positive posterolateral margins at radical prostatectomy: implications for planning of nerve‐sparing surgery
Aims: Radical prostatectomy (RP) for prostate cancer is frequently complicated by erectile dysfunction and urinary incontinence. However, sparing of the nerve bundles adjacent to the posterolateral sides of the prostate reduces the number of complications at the risk of positive surgical margins. Preoperative selection of men eligible for safe, nerve‐sparing surgery is therefore needed. Our aim was to identify pathological factors associated with positive posterolateral surgical margins in men undergoing bilateral nerve‐sparing RP.Methods and results: Prostate cancer patients undergoing RP with standardised intra‐operative surgical margin assessment according to the NeuroSAFE technique were included. Preoperative biopsies were reviewed for grade group (GG), cribriform and/or intraductal carcinoma (CR/IDC), perineural invasion (PNI), cumulative tumour length and extraprostatic extension (EPE). Of 624 included patients, 573 (91.8%) received NeuroSAFE bilaterally and 51 (8.2%) unilaterally, resulting in a total of 1197 intraoperative posterolateral surgical margin assessments. Side‐specific biopsy findings were correlated to ipsilateral NeuroSAFE outcome. Higher biopsy GG, CR/IDC, PNI, EPE, number of positive biopsies and cumulative tumour length were all associated with positive posterolateral margins. In multivariable bivariate logistic regression, ipsilateral PNI [odds ratio (OR) = 2.98, 95% confidence interval (CI) = 1.62–5.48; P < 0.001] and percentage of positive cores (OR = 1.18, 95% CI = 1.08–1.29; P < 0.001) were significant predictors for a positive posterolateral margin, while GG and CR/IDC were not.Conclusions: Ipsilateral PNI and percentage of positive cores were significant predictors for a positive posterolateral surgical margin at RP. Biopsy PNI and tumour volume can therefore support clinical decision‐making on the level of nerve‐sparing surgery in prostate cancer patients.
- 4 May 2023
- Published by Wiley in Histopathology
- Vol. 83 (3) , 348-356
Open AccessBiopsy prostate cancer perineural invasion and tumour load are associated with positive posterolateral margins at radical prostatectomy: implications for planning of nerve‐sparing surgery
Aims: Radical prostatectomy (RP) for prostate cancer is frequently complicated by erectile dysfunction and urinary incontinence. However, sparing of the nerve bundles adjacent to the posterolateral sides of the prostate reduces the number of complications at the risk of positive surgical margins. Preoperative selection of men eligible for safe, nerve‐sparing surgery is therefore needed. Our aim was to identify pathological factors associated with positive posterolateral surgical margins in men undergoing bilateral nerve‐sparing RP.Methods and results: Prostate cancer patients undergoing RP with standardised intra‐operative surgical margin assessment according to the NeuroSAFE technique were included. Preoperative biopsies were reviewed for grade group (GG), cribriform and/or intraductal carcinoma (CR/IDC), perineural invasion (PNI), cumulative tumour length and extraprostatic extension (EPE). Of 624 included patients, 573 (91.8%) received NeuroSAFE bilaterally and 51 (8.2%) unilaterally, resulting in a total of 1197 intraoperative posterolateral surgical margin assessments. Side‐specific biopsy findings were correlated to ipsilateral NeuroSAFE outcome. Higher biopsy GG, CR/IDC, PNI, EPE, number of positive biopsies and cumulative tumour length were all associated with positive posterolateral margins. In multivariable bivariate logistic regression, ipsilateral PNI [odds ratio (OR) = 2.98, 95% confidence interval (CI) = 1.62–5.48; P < 0.001] and percentage of positive cores (OR = 1.18, 95% CI = 1.08–1.29; P < 0.001) were significant predictors for a positive posterolateral margin, while GG and CR/IDC were not.Conclusions: Ipsilateral PNI and percentage of positive cores were significant predictors for a positive posterolateral surgical margin at RP. Biopsy PNI and tumour volume can therefore support clinical decision‐making on the level of nerve‐sparing surgery in prostate cancer patients.
- Open Access
- 7 April 2023
- Published by Elsevier in European Urology Focus
- Vol. 9 (5) , 824-831
Urinary Incontinence and Sexual Function After the Introduction of NeuroSAFE in Radical Prostatectomy for Prostate Cancer
- 7 April 2023
- Published by Elsevier in European Urology Focus
- Vol. 9 (5) , 824-831
Open AccessUrinary Incontinence and Sexual Function After the Introduction of NeuroSAFE in Radical Prostatectomy for Prostate Cancer